<SEC-DOCUMENT>0001140361-23-042366.txt : 20230901
<SEC-HEADER>0001140361-23-042366.hdr.sgml : 20230901
<ACCEPTANCE-DATETIME>20230901160707
ACCESSION NUMBER:		0001140361-23-042366
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20230831
FILED AS OF DATE:		20230901
DATE AS OF CHANGE:		20230901

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			GNI Group Ltd.
		CENTRAL INDEX KEY:			0001958461

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		231232548

	BUSINESS ADDRESS:	
		STREET 1:		NIHONBASHI-HONCHO YS BLDG 3F
		STREET 2:		2-2-2 NIHONBASHI-HONCHO, CHUO-KU
		CITY:			TOKYO
		STATE:			M0
		ZIP:			103-0023
		BUSINESS PHONE:		81-3-6214-3600

	MAIL ADDRESS:	
		STREET 1:		NIHONBASHI-HONCHO YS BLDG 3F
		STREET 2:		2-2-2 NIHONBASHI-HONCHO, CHUO-KU
		CITY:			TOKYO
		STATE:			M0
		ZIP:			103-0023

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			GNI Hong Kong Ltd
		CENTRAL INDEX KEY:			0001958509

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		231232547

	BUSINESS ADDRESS:	
		STREET 1:		12/F ELITE CENTRE
		STREET 2:		22 HUNG TO ROAD
		CITY:			KWUN TONG KL
		STATE:			K3
		ZIP:			0000
		BUSINESS PHONE:		81-3-6214-3600

	MAIL ADDRESS:	
		STREET 1:		12/F ELITE CENTRE
		STREET 2:		22 HUNG TO ROAD
		CITY:			KWUN TONG KL
		STATE:			K3
		ZIP:			0000

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATALYST BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-871-0761

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2023-08-31</periodOfReport>

    <issuer>
        <issuerCik>0001124105</issuerCik>
        <issuerName>CATALYST BIOSCIENCES, INC.</issuerName>
        <issuerTradingSymbol>CBIO</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001958461</rptOwnerCik>
            <rptOwnerName>GNI Group Ltd.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>NIHONBASHI-HONCHO YS BLDG 3F</rptOwnerStreet1>
            <rptOwnerStreet2>2-2-2 NIHONBASHI-HONCHO, CHUO-KU</rptOwnerStreet2>
            <rptOwnerCity>TOKYO</rptOwnerCity>
            <rptOwnerState>M0</rptOwnerState>
            <rptOwnerZipCode>103-0023</rptOwnerZipCode>
            <rptOwnerStateDescription>JAPAN</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isTenPercentOwner>true</isTenPercentOwner>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001958509</rptOwnerCik>
            <rptOwnerName>GNI Hong Kong Ltd</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>12/F ELITE CENTRE</rptOwnerStreet1>
            <rptOwnerStreet2>22 HUNG TO ROAD</rptOwnerStreet2>
            <rptOwnerCity>KWUN TONG KL</rptOwnerCity>
            <rptOwnerState>K3</rptOwnerState>
            <rptOwnerZipCode></rptOwnerZipCode>
            <rptOwnerStateDescription>HONG KONG</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isTenPercentOwner>true</isTenPercentOwner>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Series Y Preferred Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2023-08-31</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>D</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>895.217</value>
                    <footnoteId id="F1"/>
                    <footnoteId id="F2"/>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>0</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                    <footnoteId id="F3"/>
                    <footnoteId id="F4"/>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Series Y Preferred Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2023-08-31</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>D</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>5371.303</value>
                    <footnoteId id="F1"/>
                    <footnoteId id="F2"/>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>0</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                    <footnoteId id="F5"/>
                    <footnoteId id="F6"/>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">On June 20, 2023, the Company's board of directors (the &quot;Board&quot;) declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the &quot;Preferred Stock&quot;), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company.</footnote>
        <footnote id="F2">On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated.</footnote>
        <footnote id="F3">These securities are held by GNI Group Ltd. (&quot;GNI Japan&quot;).</footnote>
        <footnote id="F4">GNI Hong Kong Ltd. (&quot;GNI HK&quot;) disclaims beneficial ownership of the securities held by GNI Japan for purposes of Rule 16a-1(a)(2), except to the extent of its pecuniary interest therein.</footnote>
        <footnote id="F5">These securities are held by GNI HK.</footnote>
        <footnote id="F6">GNI HK, through GNI Japan-affiliated entities, is a wholly-owned subsidiary of GNI Japan. GNI Japan may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the securities held by GNI HK and, therefore, a &quot;ten percent holder&quot; hereunder.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Branden Berns, as attorney-in-fact for GNI Group Ltd.</signatureName>
        <signatureDate>2023-09-01</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>/s/ Branden Berns, as attorney-in-fact for GNI Hong Kong Ltd</signatureName>
        <signatureDate>2023-09-01</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
